NO329172B1 - Fremgangsmate for seleksjon av et korrekt foldet fusjonspolypeptid - Google Patents
Fremgangsmate for seleksjon av et korrekt foldet fusjonspolypeptid Download PDFInfo
- Publication number
- NO329172B1 NO329172B1 NO20005628A NO20005628A NO329172B1 NO 329172 B1 NO329172 B1 NO 329172B1 NO 20005628 A NO20005628 A NO 20005628A NO 20005628 A NO20005628 A NO 20005628A NO 329172 B1 NO329172 B1 NO 329172B1
- Authority
- NO
- Norway
- Prior art keywords
- phage
- protease
- cleavage
- protein
- polypeptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 157
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 147
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 141
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000004927 fusion Effects 0.000 title claims abstract description 40
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 27
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 27
- 230000001902 propagating effect Effects 0.000 claims abstract description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 100
- 230000007017 scission Effects 0.000 claims description 99
- 108091005804 Peptidases Proteins 0.000 claims description 87
- 239000004365 Protease Substances 0.000 claims description 85
- 230000027455 binding Effects 0.000 claims description 43
- 210000002845 virion Anatomy 0.000 claims description 31
- 239000003550 marker Substances 0.000 claims description 20
- 239000007790 solid phase Substances 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 8
- 241000700605 Viruses Species 0.000 abstract description 45
- 102000035195 Peptidases Human genes 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 74
- 235000019419 proteases Nutrition 0.000 description 64
- 235000018102 proteins Nutrition 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 60
- 108090000631 Trypsin Proteins 0.000 description 50
- 102000004142 Trypsin Human genes 0.000 description 50
- 239000012588 trypsin Substances 0.000 description 49
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 41
- 101710183938 Barstar Proteins 0.000 description 30
- 230000017854 proteolysis Effects 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 29
- 101710125418 Major capsid protein Proteins 0.000 description 27
- 101710132601 Capsid protein Proteins 0.000 description 26
- 101710094648 Coat protein Proteins 0.000 description 26
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 26
- 101710141454 Nucleoprotein Proteins 0.000 description 26
- 101710083689 Probable capsid protein Proteins 0.000 description 26
- 239000013598 vector Substances 0.000 description 25
- 239000012634 fragment Substances 0.000 description 24
- 238000003752 polymerase chain reaction Methods 0.000 description 24
- 239000002245 particle Substances 0.000 description 22
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 21
- 108090001109 Thermolysin Proteins 0.000 description 20
- 108090000195 villin Proteins 0.000 description 19
- 230000002797 proteolythic effect Effects 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 150000001413 amino acids Chemical group 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000002823 phage display Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 101150040383 pel2 gene Proteins 0.000 description 10
- 101150050446 pelB gene Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000724791 Filamentous phage Species 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000012846 protein folding Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108090000317 Chymotrypsin Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960002376 chymotrypsin Drugs 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003398 denaturant Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108090000787 Subtilisin Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000004992 fission Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 101100508919 Arabidopsis thaliana IPT6 gene Proteins 0.000 description 2
- 108050001251 Barnases Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 101710187001 DNA terminal protein Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 2
- 101150031366 P3 gene Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 101710174009 Suppressor of RNA silencing p3 Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 108020005087 unfolded proteins Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- -1 Asp-N Proteins 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 108010077781 F-actin-binding proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710179596 Gene 3 protein Proteins 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 102100031801 Nexilin Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 241000350158 Prioria balsamifera Species 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 108010003510 anhydrotrypsin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000007398 protein translocation Effects 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 101150061964 tolA gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Circuits Of Receivers In General (AREA)
- Vehicle Body Suspensions (AREA)
- Air Bags (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9810223.9A GB9810223D0 (en) | 1998-05-13 | 1998-05-13 | Selection system |
| GBGB9810228.8A GB9810228D0 (en) | 1998-05-13 | 1998-05-13 | Selection method |
| PCT/GB1999/001526 WO1999058655A2 (en) | 1998-05-13 | 1999-05-13 | Phage display selection system for folded proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005628D0 NO20005628D0 (no) | 2000-11-08 |
| NO20005628L NO20005628L (no) | 2001-01-12 |
| NO329172B1 true NO329172B1 (no) | 2010-09-06 |
Family
ID=26313668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005628A NO329172B1 (no) | 1998-05-13 | 2000-11-08 | Fremgangsmate for seleksjon av et korrekt foldet fusjonspolypeptid |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7442159B1 (de) |
| EP (2) | EP1950295A1 (de) |
| JP (2) | JP4493846B2 (de) |
| AT (1) | ATE380865T1 (de) |
| AU (1) | AU762814B2 (de) |
| CA (1) | CA2328422A1 (de) |
| CY (1) | CY1107293T1 (de) |
| DE (1) | DE69937735T2 (de) |
| DK (1) | DK1078051T3 (de) |
| ES (1) | ES2299244T3 (de) |
| GB (1) | GB2361237A (de) |
| NO (1) | NO329172B1 (de) |
| PT (1) | PT1078051E (de) |
| WO (1) | WO1999058655A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140918A0 (en) | 1998-07-27 | 2002-02-10 | Genentech Inc | Improved transformation efficiency in phage display through modification of a coat protein |
| IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
| CA2399809A1 (en) * | 2000-02-03 | 2001-08-09 | Domantis Limited | Combinatorial protein domains |
| GB0019049D0 (en) * | 2000-08-04 | 2000-09-27 | Neutec Pharma Plc | Combinatorial chemistry method |
| AU2001277614A1 (en) * | 2000-08-07 | 2002-02-18 | Domantis Limited | Novel proteins |
| DE10135039C1 (de) * | 2001-07-18 | 2003-03-13 | Nemod Immuntherapie Ag | Verfahren zur Isolierung großer Varianzen spezifischer Moleküle für ein Zielmolekül aus Phagemid-Gen-Bibliotheken |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| RU2412249C2 (ru) * | 2005-07-08 | 2011-02-20 | Юниверсити Оф Цюрих | Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов |
| GB2428293A (en) * | 2005-07-13 | 2007-01-24 | Domantis Ltd | Phage display libraries |
| US20090305898A1 (en) * | 2005-07-21 | 2009-12-10 | Ilan Morad | Methods and Compositions for Identifying a Peptide Having an Intermolecular Interaction With a Target of Interest |
| GB0515115D0 (en) | 2005-07-22 | 2005-08-31 | Isogenica Ltd | Peptide characterisation |
| CA2655933C (en) * | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| JP2011504722A (ja) | 2007-08-21 | 2011-02-17 | モルフォシス・アー・ゲー | ジスルフィド結合形成のための改良された方法 |
| CN101932608A (zh) | 2007-11-30 | 2010-12-29 | 葛兰素集团有限公司 | 抗原结合构建体 |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| MX2011005874A (es) | 2008-12-05 | 2011-06-27 | Glaxo Group Ltd | Metodos para seleccionar polipeptidos resistentes a proteasa. |
| JP2012518400A (ja) | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 多価および／または複数特異的ｒａｎｋｌ結合性構築物 |
| WO2010097386A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| US20110305692A1 (en) | 2009-02-24 | 2011-12-15 | Glaxo Group Limited | Antigen-binding contructs |
| BR112013013003A2 (pt) | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | proteína de ligação de antígeno, e, composição farmacêutica |
| DK3173427T3 (da) | 2011-03-31 | 2019-08-05 | Adc Therapeutics Sa | Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf |
| EA028886B1 (ru) | 2011-07-27 | 2018-01-31 | Глаксо Груп Лимитед | ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ |
| CA2853576A1 (en) * | 2011-10-27 | 2013-05-02 | The Governors Of The University Of Alberta | Device and method for bacterial culture and assay |
| RS58918B1 (sr) | 2012-01-09 | 2019-08-30 | Adc Therapeutics Sa | Agensi za tretman trostruko negativnog raka dojke |
| CN118146306A (zh) | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| NZ722401A (en) | 2014-01-31 | 2023-06-30 | Cytomx Therapeutics Inc | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| US20180340174A1 (en) * | 2014-11-11 | 2018-11-29 | Nanocore Aps | Method for identification of molecules with desired characteristics |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN107427577A (zh) * | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| EP3890764A2 (de) | 2018-12-06 | 2021-10-13 | CytomX Therapeutics, Inc. | Matrix-metalloproteasespaltbare und serin- oder cystein-proteasespaltbare substrate und verfahren zur verwendung davon |
| US20220228172A1 (en) * | 2019-06-21 | 2022-07-21 | Boehringer Ingelheim International Gmbh | Novel Mechanism to Control RNA Virus Replication and Gene Expression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE439435T1 (de) * | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE4122599C2 (de) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
-
1999
- 1999-05-13 DE DE69937735T patent/DE69937735T2/de not_active Expired - Lifetime
- 1999-05-13 WO PCT/GB1999/001526 patent/WO1999058655A2/en active IP Right Grant
- 1999-05-13 EP EP07023393A patent/EP1950295A1/de not_active Ceased
- 1999-05-13 ES ES99922306T patent/ES2299244T3/es not_active Expired - Lifetime
- 1999-05-13 CA CA002328422A patent/CA2328422A1/en not_active Abandoned
- 1999-05-13 PT PT99922306T patent/PT1078051E/pt unknown
- 1999-05-13 EP EP99922306A patent/EP1078051B1/de not_active Expired - Lifetime
- 1999-05-13 DK DK99922306T patent/DK1078051T3/da active
- 1999-05-13 GB GB0026143A patent/GB2361237A/en not_active Withdrawn
- 1999-05-13 AU AU39413/99A patent/AU762814B2/en not_active Expired
- 1999-05-13 JP JP2000548446A patent/JP4493846B2/ja not_active Expired - Lifetime
- 1999-05-13 AT AT99922306T patent/ATE380865T1/de active
-
2000
- 2000-11-08 NO NO20005628A patent/NO329172B1/no not_active IP Right Cessation
- 2000-11-10 US US09/710,444 patent/US7442159B1/en not_active Expired - Fee Related
-
2008
- 2008-02-29 CY CY20081100242T patent/CY1107293T1/el unknown
- 2008-10-07 US US12/246,741 patent/US8680018B2/en not_active Expired - Fee Related
-
2009
- 2009-12-25 JP JP2009294773A patent/JP5161865B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002514413A (ja) | 2002-05-21 |
| GB0026143D0 (en) | 2000-12-13 |
| AU762814B2 (en) | 2003-07-03 |
| AU3941399A (en) | 1999-11-29 |
| GB2361237A (en) | 2001-10-17 |
| NO20005628D0 (no) | 2000-11-08 |
| WO1999058655A2 (en) | 1999-11-18 |
| US7442159B1 (en) | 2008-10-28 |
| US20090203542A1 (en) | 2009-08-13 |
| JP4493846B2 (ja) | 2010-06-30 |
| JP2010148507A (ja) | 2010-07-08 |
| PT1078051E (pt) | 2008-03-17 |
| EP1078051B1 (de) | 2007-12-12 |
| US8680018B2 (en) | 2014-03-25 |
| ES2299244T3 (es) | 2008-05-16 |
| CA2328422A1 (en) | 1999-11-18 |
| DK1078051T3 (da) | 2008-04-07 |
| ATE380865T1 (de) | 2007-12-15 |
| EP1078051A2 (de) | 2001-02-28 |
| NO20005628L (no) | 2001-01-12 |
| JP5161865B2 (ja) | 2013-03-13 |
| WO1999058655A3 (en) | 2000-01-27 |
| CY1107293T1 (el) | 2012-11-21 |
| EP1950295A1 (de) | 2008-07-30 |
| DE69937735D1 (de) | 2008-01-24 |
| DE69937735T2 (de) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329172B1 (no) | Fremgangsmate for seleksjon av et korrekt foldet fusjonspolypeptid | |
| US5766905A (en) | Cytoplasmic bacteriophage display system | |
| US5733743A (en) | Methods for producing members of specific binding pairs | |
| Sternberg et al. | Display of peptides and proteins on the surface of bacteriophage lambda. | |
| EP0656941B1 (de) | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren | |
| AU655788B2 (en) | Surface expression libraries of randomized peptides | |
| US20040009507A1 (en) | Concatenated nucleic acid sequence | |
| AU3763893A (en) | Methods for producing members of specific binding pairs | |
| US20060068421A1 (en) | Compositions and methods for phage display of polypeptides | |
| CA2840650C (en) | Method of protein display | |
| Kwaśnikowski et al. | Multivalent display system on filamentous bacteriophage pVII minor coat protein | |
| Petrenko et al. | Vectors and modes of display | |
| Dani | Peptide display libraries: design and construction | |
| GB2379933A (en) | Selection system for phagemids using proteolytically sensitive helper phage | |
| US20050130124A1 (en) | Phagemid display system | |
| Studier et al. | Cytoplasmic bacteriophage display system | |
| Miertus et al. | Peptide Display Libraries: Design and Construction Maria Dani | |
| EP1811031A1 (de) | Methode zur Auswahl eines Peptids oder Polypeptids das an ein Zielmolekül bindet | |
| US20030235814A1 (en) | Compositions and methods for selecting open reading frames | |
| Pollmann | Preparation, validation and application of combinatorial phagemid libraries displaying large peptides | |
| Sche | Using cDNA phage display for the direct cloning of cellular proteins and functional identification of natural product receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |